Category: Lymphoma

Climbing stairs for cancer

Firefighter Scott Woodhouse, clad in his turnout gear, took his turn on a StairMaster outside the Fisher’s Landing Fred Meyer on Friday afternoon. Woodhouse and several other firefighters from an eight-member team rotated 20- to 30-minute shifts on the exercise machine over four hours.

Gene Therapy Shows Promise for Aggressive Lymphoma

An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy’s developers report. Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment’s maker, Kite Pharma of Santa Monica, Calif.

Gene therapy to fight a blood cancer succeeds in major study

An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.

Chugai’s ALK Inhibitor “Alecensa ” Approved in Taiwan

“We believe that the approval of Alecensa by the TFDA would bring the great news to Taiwanese patients who are fighting against this disease,” said Dr. Yasushi Ito, Chugai’s Senior Vice President, Head of Project & Lifecycle Management Unit. “We are pleased that Alecensa created by Chugai will contribute to the treatment of ALK-positive NSCLC.”

Runners honor loved ones 28 minutes ago

An early morning cold front didn’t keep Tom Curtis from competing in the Citizens Run Against Cancer half-marathon and 5K on Saturday. He was racing for his father, who passed away from Hodgkin’s disease in 1972 when he was 12 years old, and his wife, who is now cancer-free after being diagnosed with breast cancer 10 years ago.

When cancer treatments do more harm than good

When my 80-year-old father was diagnosed with Hodgkin’s disease, he was so weak that he could no longer walk, and his oncologist worried that chemotherapy might do more harm than good. But there was a new drug available, a “targeted therapy” that uses antibodies to destroy cancer cells while apparently leaving the rest of the patient’s cells alone.

Celltrion’s Rituxan biosimilar wins Eur…

South Korea’s Celltrion announced Wednesday that the European Medicines Agency has granted sales approval to Truxima, its biosimilar drug referencing Roche’s blockbuster lymphatic cancer drug Rituxan. Truxima is the first ever Rituxan biosimilar to be approved by the European drug regulator, as well as the first ever Europe-approved biosimilar monoclonal antibody used to target cancer.

Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation

Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration has granted Fast Track designation to its lead oncology product CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus . CMD-003, also known as baltaleucel-T, is an investigational therapy in which the patient’s T cells are activated to kill malignant cells expressing EBV antigens.

a Guns & Ice Creama

Father Dominic Roscioli first met 10-year-old Andrew at the Hole in the Wall Gang Camp, in Ashford, Conn. Diagnosed with brain cancer, the young boy had an infectious sense of humor, playing tricks on the camp counselors and running away from them whenever possible.

Will Seattle Genetics’ Deal With Immunomedics Get Scuttled?

The deal could be a big win for Seattle Genetics, but it doesn’t have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC — the beneficial owner of 9.9% of Immunomedics shares — said Immunomedics’ board of directors is “giving away its crown jewel.”

Dancing the cancer away

… organization raising money to fight pediatric cancer. He’s in his fourth year at the University of Iowa, majoring in health and human physiology with an interest in nursing. It also puts him on the pre-med route, should he decide to become a doctor. …

Thousands raised for children’s hospital

Staff at a Banbury nursery rallied together to raise funds for a hospital ward after one of their own children was diagnosed with a rare type of cancer. Four-year -old Alan Moulder of Banbury was diagnosed with Burkitt’s Lymphoma in September last year.

Cyclophosphamide vs salvage chemotherapy plus G-CSF as…

Autologous hematopoietic stem cell transplantation is the standard treatment option for multiple myeloma and relapsed non-Hodgkin’s lymphoma patients. 2 Chemo-mobilization success depends on the patient’s age, apheresis timing, chemotherapy and immunomodulatory regimens as well as chemotherapy-related adverse events .

Novartis Signals Growing Ambitions for CAR-T Cancer Treatments

Novartis AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumor-ridden patients. Europe’s second-biggest drugmaker is planning to test its CAR-T treatments — which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient’s body — on lethal cancers of the brain, pancreas, colon, ovary and lung.

Futility

This past December was a hard month. Bigelow lab where I work, lost our director, Graham Shimmield to colon cancer, and we lost a trustee to cancer, I lost a cousin to ovarian cancer, and a colleague lost her mother, also to cancer.

Student of the Year candidate on how to change a life

It was when he committed to be a Student of the Year candidate for the Leukemia and Lymphoma Society , the world’s largest voluntary health agency dedicated to blood cancer research. Israel, a sophomore at Loyola High School in Los Angeles, is one of 14 L.A. area students accepted into the Students of the Year program.

Camp Lejeune veterans eligible for disability

The US Department of Veterans Affairs is proposing to grant disability benefits for eight diseases for any active-duty, reserve or National Guard personnel who served at least 30 days at Camp Lejeune, North Carolina, between Aug. 1, 1953 and Dec. 31, 1987. Widows of these service personnel who died as a result of being afflicted with these diseases will also be eligible for death benefits, including a monthly stipend of approximately $1,250 and possible free health insurance for life.